Search

Your search keyword '"Danni Yu"' showing total 162 results

Search Constraints

Start Over You searched for: Author "Danni Yu" Remove constraint Author: "Danni Yu"
162 results on '"Danni Yu"'

Search Results

1. Is executive compensation aligned with the company’s ESG objectives? Evidence from Chinese listed companies based on the PSM-DID approach

2. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials

3. ESG uncertainty, investor attention and stock price crash risk in China: evidence from PVAR model analysis

4. Impact of digital city competitiveness on total factor productivity in the commercial circulation industry: evidence from China’s emerging first-tier cities

5. In-situ growth of low-dimensional perovskite-based insular nanocrystals for highly efficient light emitting diodes

6. ESG performance, investor attention, and company reputation: Threshold model analysis based on panel data from listed companies in China

7. Biomimetic electrospinning for fabrication of poly(lactic acid)/graphite oxide/poly(dopamine) nanofiber membrane

8. Preparation and adsorption application of PLA/GO/PDA nanofiber membrane

10. State ownership, information asymmetry and cash holding: Impact of COVID-19 on Chinese-listed firms

11. The impact of innovation on CO2 emissions: The threshold effect of financial development

12. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

13. Genre as an Act of Positioning

14. Kinetics of Interfacial Lithium-ion Transfer between a Graphite Negative Electrode and a Li2S-P2S5 Glassy Solid Electrolyte

15. FengLiao affects gut microbiota and the expression levels of Na+/H+ exchangers, aquaporins and acute phase proteins in mice with castor oil-induced diarrhea.

18. Facile Fabrication of ZnO/TiO2 Heterogeneous Nanofibres and Their Photocatalytic Behaviour and Mechanism towards Rhodamine B

19. Expression of miRNAs and their cooperative regulation of the pathophysiology in traumatic brain injury.

20. A coastal cline in sodium accumulation in Arabidopsis thaliana is driven by natural variation of the sodium transporter AtHKT1;1.

23. High-member low-dimensional Sn-based perovskite solar cells

24. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02

26. Supplementary Figure S2 from A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

27. Figure S1 from Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

28. Supplementary Data from Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

29. Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

30. Supplementary Figure S1 from Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

31. Data from Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

32. Supplemental Figure 3 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

33. Supplementary Table S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

34. Data from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

35. Supplemental Figure 1 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

36. Supplemental Figure 4 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

37. Supplementary Figure S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

38. Supplemental Figure 5 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

39. Supplementary Table S2 from Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

40. Supplementary Methods from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

41. Supplemental Table 1 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

42. Supplemental Figure 2 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

43. Supplemental Table 2 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

46. Quantum-size-tuned heterostructures enable efficient and stable inverted perovskite solar cells

50. Dehydration-Reaction-Based Low-Temperature Synthesis of Amorphous SnOx for High-Performance Perovskite Solar Cells

Catalog

Books, media, physical & digital resources